Peter J. Bugelski

6.4k total citations
137 papers, 5.2k citations indexed

About

Peter J. Bugelski is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Peter J. Bugelski has authored 137 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Immunology, 39 papers in Molecular Biology and 27 papers in Oncology. Recurrent topics in Peter J. Bugelski's work include HIV Research and Treatment (19 papers), Monoclonal and Polyclonal Antibodies Research (16 papers) and HIV/AIDS drug development and treatment (15 papers). Peter J. Bugelski is often cited by papers focused on HIV Research and Treatment (19 papers), Monoclonal and Polyclonal Antibodies Research (16 papers) and HIV/AIDS drug development and treatment (15 papers). Peter J. Bugelski collaborates with scholars based in United States, United Kingdom and Netherlands. Peter J. Bugelski's co-authors include Richard Kirsh, George Poste, Thomas J. Dougherty, Carl W. Porter, T K Hart, George Treacy, Patricia Rafferty, Glenn F. Rush, Timothy K. Hart and Pauline L. Martin and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Blood and Circulation Research.

In The Last Decade

Peter J. Bugelski

133 papers receiving 4.9k citations

Peers

Countries citing papers authored by Peter J. Bugelski

Since Specialization

Citations

This map shows the geographic impact of Peter J. Bugelski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter J. Bugelski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter J. Bugelski more than expected).

Fields of papers citing papers by Peter J. Bugelski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter J. Bugelski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter J. Bugelski. The network helps show where Peter J. Bugelski may publish in the future.

Co-authorship network of co-authors of Peter J. Bugelski

This figure shows the co-authorship network connecting the top 25 collaborators of Peter J. Bugelski. A scholar is included among the top collaborators of Peter J. Bugelski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter J. Bugelski. Peter J. Bugelski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Engineering Peptide Therapeutics Using MIMETIBODY™ Technology 2013 ·Methods in molecular biology ·Kristen Picha, Chichi Huang, Peter J. Bugelski, Karyn T. O’Neil	2
2	A Novel EPO Receptor Agonist Improves Glucose Tolerance via Glucose Uptake in Skeletal Muscle in a Mouse Model of Diabetes 2011 ·Experimental Diabetes Research ·(unknown), Tatiana Ort, Ian E. James, Peter J. Bugelski, (unknown), (unknown), Elsbet Pieterman, Anita M. van den Hoek, Louis M. Havekes, William H. duBell, (unknown), Kristen Picha	14
3	Pharmacokinetics and Pharmacodynamics of an EPO-Mimetic Fusion Protein in a Model of Chronic Renal Insufficiency Anemia 2010 ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Chichi Huang, Peter J. Bugelski	2
4	Myelodysplasia and anemia of chronic disease in human tumor necrosis factor‐α transgenic mice 2008 ·Cytometry Part A ·Renold J. Capocasale, (unknown), (unknown), Nicole Stowell, John A. Quinn, Patricia Rafferty, (unknown), Eva Emmell, Peter J. Bugelski	11
5	Pharmacodynamics of Recombinant Human Erythropoietin in Murine Bone Marrow 2007 ·Pharmaceutical Research ·Peter J. Bugelski, (unknown), (unknown), (unknown), (unknown), (unknown), Paul W. Fisher, Ian E. James, (unknown), Renold J. Capocasale	17
6	A statistical pattern recognition approach for determining cellular viability and lineage phenotype in cultured cells and murine bone marrow 2007 ·Cytometry Part A ·John A. Quinn, Paul W. Fisher, Renold J. Capocasale, (unknown), Moshe Kam, Peter J. Bugelski, (unknown)	15
7	Extracellular Matrix Metalloproteinase Inducer Stimulates Tumor Angiogenesis by Elevating Vascular Endothelial Cell Growth Factor and Matrix Metalloproteinases 2005 ·Cancer Research ·Yi Tang, Marian T. Nakada, Prabakaran Kesavan, Francis L. McCabe, Hillary J. Millar, Patricia Rafferty, Peter J. Bugelski, Yan Li	297
8	Therapeutic Dosing with Anti-Interleukin-13 Monoclonal Antibody Inhibits Asthma Progression in Mice 2005 ·Journal of Pharmacology and Experimental Therapeutics ·Gaoyun Yang, Lily Li, A. Paige Davis Volk, Eva Emmell, Ted Petley, Jill Giles‐Komar, Patricia Rafferty, Mani Lakshminarayanan, Don E. Griswold, Peter J. Bugelski, Anuk Das	73
9	Principal component analysis of mass spectra of peptides generated from the tryptic digestion of protein mixtures 2001 ·Rapid Communications in Mass Spectrometry ·Duncan Bryant, (unknown), (unknown), (unknown), Peter J. Bugelski, William A. Neville, (unknown), Patrick Camilleri	15
10	Evaluation of Alamar Blue Reduction for the In Vitro Assay of Hepatocyte Toxicity 1999 ·Toxicology in Vitro ·M. R. Slaughter, Peter J. Bugelski, Peter J. O’Brien	40
11	Relationships between antibodies against human soluble complement receptor 1 (hsCR1) from various species 1996 ·Journal of Clinical Immunology ·(unknown), Peter J. Bugelski, Johanne Kaplan, Daniel E. Everitt, (unknown), Diane K. Jorkasky, Steven C. Boike, Frederick A. DeClement, Francis D. Moore, Danuta J. Herzyk	2
12	Effect of TNFα production inhibitors BRL 61063 and pentoxifylline on the response of rats to poly I:C 1995 ·Toxicology ·Johanne Kaplan, Danuta J. Herzyk, (unknown), Joan O'Leary Bartus, Klaus Esser, Peter J. Bugelski	9
13	Morphometric analysis of envelope glycoprotein gp120 distribution on HIV-1 virions. 1993 ·Journal of Histochemistry & Cytochemistry ·T K Hart, (unknown), John Ventre, Peter J. Bugelski	16
14	Effect of a Human Immunodeficiency Virus Protease Inhibitor on Human Monocyte Function 1992 ·AIDS Research and Human Retroviruses ·Peter J. Bugelski, Johanne Kaplan, Timothy K. Hart, Joanne M. Miller, Jeffrey T. Laydon, John C. Lee, Geoffrey B. Dreyer, Richard Kirsh	18
15	Strong Association of Simian Immunodeficiency Virus (SIVagm) Envelope Glycoprotein Heterodimers: Possible Role in Receptor-Mediated Activation 1992 ·AIDS Research and Human Retroviruses ·Jonathan S. Allan, Evelyn Whitehead, (unknown), Mary K. Short, Patrick Kanda, Timothy K. Hart, Peter J. Bugelski	22
16	Morphometric Analysis of Recombinant Soluble CD4-Mediated Release of the Envelope Glycoprotein gp120 from HIV-1 1990 ·AIDS Research and Human Retroviruses ·Richard Kirsh, Timothy K. Hart, Harma Ellens, Joanne M. Miller, (unknown), Dennis M. Lambert, Jeffry J. Leary, Peter J. Bugelski	70
17	A new cytochemical method for ultrastructural detection of liposomes in tissues in vivo. 1989 ·Journal of Histochemistry & Cytochemistry ·Peter J. Bugelski, D. E. Gennaro, George Poste, Sylvia Hoffstein	9
18	Modulation of Rat Bronchoalveolar Lavage Cell Function by the Intratracheal Delivery of Interferon-γ 1988 ·Journal of Interferon Research ·A M Badger, Paul C. Meunier, (unknown), Peter J. Bugelski	14
19	An Emulsion Formulation of Amphotericin B Improves the Therapeutic Index When Treating Systemic Murine Candidiasis 1988 ·The Journal of Infectious Diseases ·Richard Kirsh, Robert M. Goldstein, Joan B. Tarloff, (unknown), J. E. Hook, Nasser H. Hanna, Peter J. Bugelski, George Poste	89
20	Drug Delivery to Macrophages for the Therapy of Cancer and Infectious Diseases 1987 ·Annals of the New York Academy of Sciences ·Richard Kirsh, Peter J. Bugelski, George Poste	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact